Larimar Therapeutics
LRMR
136 hedge funds and large institutions have $277M invested in Larimar Therapeutics in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 19 closing their positions.
834% more call options, than puts
Call options by funds: $682K | Put options by funds: $73K
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
2% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 44
1% more capital invested
Capital invested by funds: $275M → $277M (+$2.2M)
0% more funds holding
Funds holding: 136 → 136 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14.95% less ownership
Funds ownership: 99.89% → 84.95% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.89M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$3.78M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.39M |
| 5 |
BlackRock
New York
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.5M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$10.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.14M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.73M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$3.49M |
LRMR Hedge Fund Activity: Q4 2025 in Review
136 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2025, worth a combined $277M — up 0.8% from $275M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LRMR positions and 19 closed out — a net gain of 3 holders — while 45 added to existing stakes and 44 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $3.89M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.
- 136 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $277M of Larimar Therapeutics stock for Q4 2025, up 0.8% quarter-over-quarter.
- 22 funds opened new Larimar Therapeutics positions in Q4 2025 and 19 closed out, a net change of +3 holders.
- The largest Larimar Therapeutics buyer in Q4 2025 was AIGH Capital Management, an estimated $3.89M added.
- The largest Larimar Therapeutics seller in Q4 2025 was RA Capital Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2025.